"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
Descriptor ID |
D000911
|
MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 12 | 11 | 23 |
1995 | 7 | 17 | 24 |
1996 | 4 | 11 | 15 |
1997 | 4 | 7 | 11 |
1998 | 6 | 16 | 22 |
1999 | 10 | 18 | 28 |
2000 | 7 | 12 | 19 |
2001 | 14 | 20 | 34 |
2002 | 11 | 16 | 27 |
2003 | 15 | 15 | 30 |
2004 | 23 | 16 | 39 |
2005 | 25 | 20 | 45 |
2006 | 26 | 15 | 41 |
2007 | 30 | 13 | 43 |
2008 | 23 | 21 | 44 |
2009 | 32 | 19 | 51 |
2010 | 40 | 24 | 64 |
2011 | 19 | 13 | 32 |
2012 | 17 | 11 | 28 |
2013 | 18 | 8 | 26 |
2014 | 18 | 13 | 31 |
2015 | 11 | 7 | 18 |
2016 | 16 | 6 | 22 |
2017 | 27 | 10 | 37 |
2018 | 23 | 14 | 37 |
2019 | 20 | 10 | 30 |
2020 | 14 | 12 | 26 |
2021 | 10 | 18 | 28 |
2022 | 3 | 18 | 21 |
2023 | 2 | 8 | 10 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.
-
MHC Tetramers Specifically Identify High- and Low-avidity Donor-specific B Cells in Transplantation Tolerance and Rejection. Transplantation. 2023 Dec 01; 107(12):2526-2532.
-
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
-
Biochemical and biophysical characterization of natural polyreactivity in antibodies. Cell Rep. 2023 10 31; 42(10):113190.
-
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2024 02; 19(2):285-296.
-
Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic? Blood Adv. 2023 08 08; 7(15):4112-4123.
-
A humanized monoclonal antibody targeting protein a promotes opsonophagocytosis of Staphylococcus aureus in human umbilical cord blood. Vaccine. 2023 08 07; 41(35):5079-5084.
-
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296.
-
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. J Immunother Cancer. 2023 06; 11(6).